Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib With Sapacitabine in BRCA Mutant Breast Cancer
NCT03641755Phase 1Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Oct 2018
- Primary completion
- Apr 2022
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label trial of sapacitabine in breast cancer (4 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoints: Maximum Tolerated Dose up to 41 months, Recommended Phase II dose up to 41 months and 1 more. Started Oct 2018; status: active, not recruiting.
02
Drugs
sapacitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03641755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03641755.